Company Filing History:
Years Active: 2005-2012
Title: The Innovative Contributions of Mona Møller
Introduction
Mona Møller is a prominent inventor based in Porsgrunn, Norway. She has made significant strides in the field of cancer research, holding a total of 7 patents. Her work focuses on developing novel therapeutic approaches to combat cancer through innovative polypeptides and nucleic acids.
Latest Patents
Møller's latest patents include groundbreaking inventions such as nucleic acids encoding novel TERT polypeptides. This invention relates to polypeptides and DNA encoding these polypeptides, which are capable of eliciting an immune reaction against cancer. Additionally, she has developed methods for generating T lymphocytes that can recognize and destroy tumor cells, along with pharmaceutical compositions for the treatment, prophylaxis, or diagnosis of cancer. Another significant patent involves isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer. These isolated peptides can elicit T cell immunity against cells harboring genes with such mutations, leading to the development of cancer vaccines and therapeutically effective compositions.
Career Highlights
Mona Møller is currently associated with Gemvax AS, where she continues her research and development efforts. Her innovative contributions have positioned her as a key figure in the field of cancer immunotherapy.
Collaborations
Møller collaborates with notable colleagues such as Jon Amund Eriksen and Gustav Gaudernack, enhancing the impact of her research through teamwork and shared expertise.
Conclusion
Mona Møller's work exemplifies the vital role of innovation in cancer research. Her patents and collaborations contribute significantly to the advancement of therapeutic strategies against cancer.